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Impact of Stent Overlap on Angiographic
and Long-Term Clinical Outcome in Patients
Undergoing Drug-Eluting Stent Implantation
Lorenz Räber, MD,* Peter Jüni, MD,†‡ Lukas Löffel, BA,* Simon Wandel, PHD, MSC,‡
Stéphane Cook, MD,* Peter Wenaweser, MD,* Mario Togni, MD,* Rolf Vogel, MD, MSC,*
Christian Seiler, MD,* Franz Eberli, MD,§ Thomas Lüscher, MD, Bernhard Meier, MD,*
Stephan Windecker, MD*†
Bern and Zurich, Switzerland
Objectives We compared the angiographic and long-term clinical outcomes of patients with and without overlap of drug-
eluting stents (DES).
Background DES overlap has been associated with delayed healing and increased inflammation in experimental studies, but
its impact on clinical outcome is not well established.
Methods We analyzed the angiographic and clinical outcomes of 1,012 patients treated with DES in the SIRTAX (Sirolimus-
Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) trial according to the presence or absence of
stent overlap and the number of stents per vessel: 134 (13.2%) patients with multiple DES in a vessel with overlap,
199 (19.7%) patients with multiple DES in a vessel without overlap, and 679 (67.1%) patients with 1 DES per vessel.
Results Angiographic follow-up at 8 months showed an increased late loss in DES overlap patients (0.33  0.61 mm)
compared with the other groups (0.18  0.43 mm and 0.15  0.38 mm, p  0.01). The smallest minimal lu-
men diameter was located at the zone of stent overlap in 17 (68%) of 25 patients with stent overlap who under-
went target lesion revascularization. Major adverse cardiac events were more common in patients with DES
overlap (34 events, 25.4%) than in the other groups (42 events, 21.1% and 95 events, 14.0%) at 3 years (p 
0.01). Both the risk of target lesion revascularization (20.2% vs. 16.1% vs. 9.7%, p  0.01) and the composite
of death or myocardial infarction (17.2% vs. 14.1% vs. 9.1%, p  0.01) were increased in patients with DES
overlap compared with the other groups.
Conclusions DES overlap occurs in 10% of patients undergoing percutaneous coronary intervention in routine clinical practice
and is associated with impaired angiographic and long-term clinical outcome, including death or myocardial infarc-
tion. (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization; NCT00297661). (J Am Coll
Cardiol 2010;55:1178–88) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.052p
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ccepted November 2, 2009.lete stent coverage (1–3). Clinical outcome of patients with
verlapping bare-metal stents (BMS) has been found to be
nferior to that of patients treated with a single BMS, largely
elated to increased rates of target lesion revascularization
TLR) (4–7). The potent suppression of neointimal hyper-
lasia afforded by first-generation drug-eluting stents
DES) with a reduction in clinical and angiographic reste-
osis raised hopes of further improvement of results in
atients with stent overlap (8–12). Yet, clinical outcomes of
verlapping DES demonstrated conflicting results. A
ooled analysis of studies assessing clinical outcomes of
verlapping sirolimus-eluting stents (SES) showed similar
ates of ischemic end points and repeat revascularization at
oth 30 days and 8 months compared with a single SES,
nd a significant reduction in the need for repeat revascu-
l
o
w
m
r
fi
a
z
p
a
c
i
D
m
g
H
o
p
t
c
o
M
P
S
S
r
t
P
i
a
l
r
f
n
B
l
u
t
t
r
a
c
s
c
t
c
S
D
t
a
q
w
s
e
t
a
t
1
c
o
m
T
p
a
d
d
d
a
r
f
s
Q
g
s
t
D
a
I
s
i
B
l
m
a
A
T
q
r
o
a
L
w
d
S
w
o
s
2
D
c
i
t
m
o
g
1179JACC Vol. 55, No. 12, 2010 Räber et al.
March 23, 2010:1178–88 Impact of Stent Overlaparization compared with a BMS (13). Conversely, multiple
verlapping paclitaxel-eluting stents (PES) were associated
ith improved efficacy but increased rates of periprocedural
yonecrosis compared with overlapping BMS, presumably
elated to more frequent side branch compromise (14,15).
More recently, safety concerns surfaced with the use of
rst-generation DES during long-term follow-up, presum-
bly related to delayed healing and impaired endotheliali-
ation (16). The latter phenomenon may be particularly
ronounced at sites of DES overlap owing to increased drug
nd polymer concentrations. One experimental study spe-
ifically addressed the differential response of arterial heal-
ng at sites of DES overlap. Compared with nonoverlapping
ES and BMS sites, overlapping DES segments showed
ore neutrophils, eosinophils, and fibrin deposition, sug-
esting impaired healing and increased inflammation (17).
owever, the impact of these findings on long-term clinical
utcomes is not well established. The objective of the
resent study was to compare the angiographic and long-
erm clinical outcomes of patients with overlapping DES
ompared with those of patients with multiple DES with no
verlap, or a single DES implanted in a vessel.
ethods
atient population and intervention. The design of the
IRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting
tents for Coronary Revascularization) trial was previously
eported (18). It was an observer-blind, randomized, con-
rolled trial comparing the safety and efficacy of SES and
ES in 1,012 patients undergoing percutaneous coronary
nterventions. Eligible patients had a history of stable
ngina or acute coronary syndrome and presented with at
east 1 lesion with a stenosis 50% in a vessel with a
eference vessel diameter between 2.25 and 4.0 mm suitable
or stent implantation. There were no limitations on the
umber of treated lesions and vessels or lesion length.
efore or at the time of the procedure, patients received at
east 100 mg of aspirin, a loading dose of clopidogrel, and
nfractionated heparin (70 to 100 U/kg body weight). After
he procedure, all patients were prescribed lifelong aspirin
herapy and clopidogrel for 12 months. All patients were
equested at the time of randomization to undergo repeat
ngiography at 8 months. Subsequently, a research nurse
ontacted all patients and asked them at least once to
chedule an appointment for repeat angiography. The study
omplied with the Declaration of Helsinki regarding inves-
igations in humans and was approved by the research ethics
ommittees at the University Hospitals of Bern and Zurich,
witzerland. All patients provided written informed consent.
efinition and end points. Stent overlap was defined as
he presence of 2 stents within a single treated lesion and
n overlapping stent zone of at least 1 mm, as determined by
uantitative coronary angiography. Overlapping stent zones tere identified based on the po-
ition of the stent balloon mark-
rs of the second stent relative to
he first stent. Adverse events were
ssessed during the hospitaliza-
ion, at 1, 6, and 9 months and at
, 2, and 3 years. An independent
linical events committee unaware
f the patient’s treatment assign-
ent adjudicated all end points.
he prespecified primary end
oint was a composite of major
dverse cardiac events (MACE),
efined as cardiac death, myocar-
ial infarction (MI), or ischemia-
riven TLR at 9 months. Second-
ry end points included ischemia-driven TLR, target vessel
evascularization, or target vessel failure at all scheduled
ollow-up visits. Definitions of ischemia-driven TLR, MI, and
tent thrombosis were published previously (18).
uantitative coronary angiography. Coronary angio-
rams were digitally recorded at baseline, immediately after
tent implantation, and at follow-up and were assessed at
he angiographic core laboratory of the University of Bern.
igital angiograms were analyzed with the use of an
utomated edge-detection system (CAAS II, Pie Medical
maging, Maastricht, the Netherlands). Quantitative mea-
urements included the reference vessel diameter, the min-
mal lumen diameter, and percentage of diameter stenosis.
inary restenosis was defined as stenosis50% in the target
esion at angiographic follow-up. All angiographic measure-
ents of the target lesion were obtained within the stent
nd the areas 5 mm proximal and distal to the stent edge.
ll lesions of patients with stent overlap who underwent
LR at any time point up to 3 years were analyzed by
uantitative coronary angiography to determine the zone of
estenosis triggering the repeat revascularization and the site
f minimal lumen diameter. The restenosis pattern was
nalyzed independently by 2 fellows in cardiology (L.R. and
.L.). In cases of disagreement, an external cardiologist who
as not involved in the SIRTAX trial made the final
ecision.
tatistical analysis. For the purpose of the present study,
e performed an analysis of clinical and angiographic
utcomes stratified according to the presence or absence of
tent overlap. Among patients without overlap, we specified
groups: the first group consisted of patients with multiple
ES within a vessel but no overlap, and the second group
onsisted of the remaining patients who had a single DES
mplanted within a vessel.
Patient characteristics at baseline were compared among
he 3 patient groups using chi-square tests for binary and
aximum-likelihood linear regression models for continu-
us outcomes, which allowed the comparison of the 3
roups. In cases of multiple lesions in a patient, we restricted
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationhe analysis to the lesions that led to the final classification
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Impact of Stent Overlap March 23, 2010:1178–88f patients: If patients were classified as having stent
verlap, we excluded lesions without documented overlap
n  64 lesions); if patients were classified as having
ultiple DES in a vessel but no overlap, we excluded lesions
n vessels with only 1 DES implanted (n  34 lesions).
esion characteristics were compared using maximum-
ikelihood logistic and linear regression models with robust
tandard errors that accounted for the correlation of lesion
haracteristics within patients. We then used Cox propor-
ional hazards models along with Wald tests to allow an
verall comparison of outcomes of all 3 groups. We per-
ormed crude analyses and analyses adjusted for the presence
r absence of diabetes, lesion length, reference vessel diam-
ter, number of lesions, stent allocation, American College
f Cardiology/American Heart Association lesion classifi-
ation, and the presence of acute coronary syndrome and
lotted Kaplan-Meier survival curves of MACE, TLR, and
he composite of death or MI. The analyses of patients and
linical outcomes were based on all 1,012 patients included
n the SIRTAX trial, with patients censored at the time of
oss to follow-up. The analysis of angiographic outcomes
as restricted to the 540 patients with available angiographic
ollow-up at 8 months. We used maximum-likelihood logistic
nd linear regression models based on robust standard errors
hat allowed for the correlation of multiple lesions within a
atient to compare the quantitative angiographic data across
roups. Then we restricted the analysis to the 27 lesions with
tent overlap that underwent TLR and used a maximum-
ikelihood logistic regression model with robust standard errors
hat allowed for the correlation of stent zones within a lesion to
erform a test for trend on the pattern of restenosis across
rdered zones: zone of overlap, zone of nonoverlap, and
one of stent border. All p values are 2 sided. Analyses were
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Multip
Overlap*
Total no. of patients 134
Age 65 yrs 45 (33.6)
Males 107 (79.9)
Diabetes mellitus 23 (17.2)
Hypertension 90 (67.2)
Hyperlipidemia 80 (59.7)
Current smoking 52 (38.8)
Previous MI 42 (31.3)
Stable angina pectoris 58 (43.3)
Acute coronary syndromes 76 (56.7)
Unstable angina 8 (6.0)
Non–ST-segment elevation MI 39 (29.1)
ST-segment elevation MI 29 (21.6)
Multivessel disease 95 (70.9)
No. of lesions per patient 1.5 (0.6)
Left ventricular ejection fraction 56.5 (10.6)
Values are n (%) or mean SD. *Patients with multiple drug-eluting ste
overlap. ‡Patients with a single stent in a vessel. §p values are for difference
MI  myocardial infarction.erformed using Stata version 10.1 software (StataCorp,
nc., College Station, Texas).
esults
aseline clinical and angiographic characteristics. A to-
al of 1,012 patients were randomly allocated to treatment
ith SES (n  503) or PES (n  509). Multiple DES in a
essel with overlap were documented in 134 (13.2%) pa-
ients with 138 lesions, multiple DES in a vessel without
verlap in 199 (19.7%) patients with 394 lesions, and a
ingle DES in a vessel in 679 (67.1%) patients with 778
esions. There were significant differences among groups in
ge, the presence of multivessel disease, and the number of
esions per patient (all p values 0.01) (Table 1). Lesion
haracteristics differed significantly among groups in all
espects except reference vessel diameter (Table 2); lesions
ith stent overlap were most complex. Procedural results are
ummarized in Table 3. Patients with DES overlap received
ore and longer stents per lesion compared with the control
roups (p  0.01) and differed in acute gain (p  0.01). The
easons for stent overlap were, in descending order (Table 4),
xcessive lesion length in relation to maximal available stent
ength (43.5%), incomplete target lesion coverage (35.5%), and
issections at the stent edges (19.6%).
linical outcomes. Clinical outcome data were complete
or 1,002 (99.0%) of 1,012 patients at 3 years of follow-up.
rude and adjusted analyses of clinical events at 3 years of
ollow-up are presented in Table 5. Compared with con-
rols, patients with DES overlap were more likely to
xperience a MACE in crude (p  0.01) and adjusted
p  0.04) analyses. The individual hazard ratio comparing
ES overlap patients with patients with multiple DES in a
nts
Single Stent‡ p Value§No Overlap†
199 679
104 (52.3) 293 (43.2) 0.01
150 (75.3) 524 (77.2) 0.63
47 (23.6) 131 (19.3) 0.28
122 (61.3) 410 (60.4) 0.34
109 (54.8) 408 (60.1) 0.40
69 (34.7) 244 (35.9) 0.74
62 (31.2) 193 (28.4) 0.65
88 (44.2) 346 (51.0) 0.10
111 (55.8) 333 (49.0) 0.26
9 (4.5) 41 (6.0)
50 (25.1) 146 (21.5)
52 (26.1) 146 (21.5)
143 (71.9) 364 (53.6) 0.01
2.2 (0.5) 1.1 (0.4) 0.01
55.7 (11.9) 57.1 (11.9) 0.35
vessel with overlap. †Patients with multiple stents in a vessel withoutle Ste
nts in a
s among groups.
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March 23, 2010:1178–88 Impact of Stent Overlapessel without overlap was 1.22 in crude analyses (95%
onfidence interval [CI]: 0.77 to 1.91, p  0.40), but 1.99
n adjusted analyses (95% CI: 1.16 to 3.41, p  0.01).
onversely, the hazard ratio comparing DES overlap pa-
ients with patients with a single DES in a vessel was 1.93
n crude analyses (95% CI: 1.3 to 2.85, p  0.01) and 1.50
n adjusted analyses (95% CI: 0.91 to 2.46, p  0.11). The
ifferences were driven by both effectiveness (crude and
djusted analyses of TLR: p  0.01 and p  0.10,
Baseline Characteristics of LesionsTable 2 Baseline Characteristics of Lesions
Mult
Overlap*
Total no. of lesions 138
Target lesion coronary artery
Left main 2 (1.5)
Left anterior descending 53 (38.4)
Left circumflex 27 (19.6)
Right 53 (38.4)
Bypass graft 3 (2.2)
ACC/AHA lesion class
A 19 (13.8)
B1 39 (28.3)
B2 44 (31.9)
C 36 (26.1)
Angiographic measures
Lesion length, mm 17.07 10.54
Reference vessel diameter, mm 2.83 0.40
Minimal lumen diameter, mm 0.41 0.45
Stenosis, % lumen diameter 85.37 15.39
Values are n (%) or mean SD. *Patients with multiple drug-eluting ste
overlap. ‡Patients with a single stent in a vessel. §p values are for diffe
sirolimus-eluting stents that accounted for the correlation of characte
ACC/AHA  American College of Cardiology/American Heart Assoc
Quantitative Procedural ResultsTable 3 Quantitative Procedural Results
M
Overlap*
Total no. of lesions 138
Procedures
No. of stents, per lesion 2.2 0.5
Stent diameter, mm 2.8 0.4
Stent length per lesion, mm 36.6 16.7
Maximal pressure, atm 14.3 2.9
Angiographic results
Final minimal lumen diameter, mm
In-stent 2.65 0.35
In-segment 2.54 0.40
Final stenosis, % of lumen diameter
In-stent 7.73 4.71
In-segment 9.24 6.85
Acute gain, mm
In-stent 2.23 0.56
In-segment 2.16 0.55
Values are mean SD. *Patients with multiple drug-eluting stents in a
‡Patients with a single stent in a vessel. §p values are for differences am
sirolimus-eluting stents that accounted for the correlation of characteristics oespectively) and safety end points (composite of death or
I: p  0.01 and p  0.02, respectively). Table 6 presents
horter-term results at 30 days of follow-up; no clear-cut
attern could be detected. There was little evidence of a
orse outcome in patients with stent overlap, but 95% CIs
ere wide. At 9 months, the pattern of MACE, TLR, and
he composite of death or MI was similar to that at 3 years.
n adjusted analyses, the hazard ratio comparing DES
verlap patients with patients with 1 stent per vessel but
tents
Single Stent‡ p Value§No Overlap†
394 778
1 (0.1) 16 (2.1) 0.01
177 (44.9) 379 (48.7)
63 (16.0) 159 (20.4)
143 (36.3) 214 (27.5)
10 (2.5) 10 (1.3)
74 (18.8) 167 (21.5) 0.01
181 (45.9) 347 (44.6)
79 (20.1) 186 (23.9)
60 (15.2) 78 (10.0)
12.62 8.71 11.11 4.87 0.01
2.80 0.41 2.84 0.41 0.28
0.64 0.47 0.49 0.42 0.01
77.40 15.24 82.91 14.05 0.01
vessel with overlap. †Patients with multiple stents in a vessel without
among groups from linear and logistic regression models using robust
f lesions within patients.
Stents
Single Stent‡ p Value§No Overlap†
394 778
1.1 0.3 1.0 0.1 0.01
2.9 0.4 2.9 0.4 0.01
17.2 8.8 16.7 6.4 0.01
14.0 3.1 14.3 3.0 0.46
2.63 0.36 2.69 0.38 0.05
2.53 0.40 2.62 0.43 0.04
7.16 4.65 6.82 5.39 0.12
8.63 6.82 8.50 7.12 0.68
1.99 0.49 2.20 0.50 0.01
1.91 0.53 2.15 0.53 0.01
ith overlap. †Patients with multiple stents in a vessel without overlap.iple S
nts in a
rencesultiple
vessel w
ong groups from linear and logistic regression models using robust
f lesions within patients.
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Impact of Stent Overlap March 23, 2010:1178–88o overlap was 2.34 for MACE (95% CI: 1.12 to 4.92), 2.77
or TLR (95% CI: 1.18 to 6.50), and 1.69 for the composite
f death or MI (95% CI: 0.60 to 4.75). The corresponding
aplan-Meier curves for MACE, TLR, and the composite
f death or MI are presented in Figure 1. Cumulative event
urves of patients with DES overlap and patients with a
ingle stent in a vessel started to diverge immediately after
andomization for all end points; curves for patients with
verlap and for patients with multiple stents in a vessel but
o overlap started to diverge only at 12 to 24 months.
ngiographic results. The angiographic follow-up was
erformed at a median of 8.3 months (interquartile range
.2 to 10.3 months) after randomization. A total of 540
53.4%) patients underwent angiography, 167 (16.5%) pa-
ients refused, 287 (28.4%) patients consented and were
nvited but did not attend angiography, 16 (1.6%) patients
ied, and 2 (0.2%) patients were lost to follow-up before
ollow-up angiography could be performed. Angiographic
ollow-up data were available for 77 patients with overlap
81 lesions), 101 patients with multiple DES in a vessel
ithout overlap (177 lesions), and 362 patients with a single
ES per vessel (413 lesions) (Table 7). Patients undergoing
ngiographic follow-up were younger (p  0.01), more
ikely to be male (p  0.01), and less likely to have diabetes
p  0.04), hypertension (p  0.04), or chest pain (p 
.01) (18). In 18 of the 77 patients with stent overlap, the
inimal lumen diameter measured immediately after the
ndex procedure was located at the zone of overlap (23.4%),
nd the subgroup of patients undergoing TLR (n  27)
howed the same pattern. The in-stent percentage diameter
tenosis was more pronounced among patients with overlap
ompared with control groups (18.8% vs. 12.2% and 10.4%,
 0.01), as were in-stent late loss (0.33 mm vs. 0.18 and
.15 mm, p  0.04) and binary in-stent restenosis (12.4%
s. 5.1% and 3.6%, p 0.01). Stent fractures were observed in
of the 77 patients with overlap at angiographic follow-up.
attern of restenosis. Twenty-seven patients with 27 le-
ions with DES overlap underwent TLR during the
ollow-up up to 3 years. Angiograms obtained before TLR
ere available for 25 of the 27 patients. Figure 2 presents
he distribution of restenoses across the different zones of
he treated lesions. Of 25 lesions, 17 (68%) had documented
inary restenosis at the zone of stent overlap as opposed to
verlapping Stents: Reason forImpl ntation per LesionTable 4 Ov rlapping Stents: Reason forOverlapping Stent Implantation per Lesion
Total no. of lesions 138 (100)
Excessive lesion length 60 (43.5)
Incomplete lesion coverage 49 (35.5)
Dissection proximal 12 (8.7)
Dissection distal 15 (10.9)
Guiding catheter dissection 1 (0.7)
Residual thrombus 1 (0.7)
alues are n (%).(24%) at the proximal stent zones without overlap, 4 g16%) at the distal stent zones without overlap, 4 (16%)
ithin the proximal edge, and 1 (4%) within the distal edge
p for trend 0.01). The minimal lumen diameter within a
reated lesion, corresponding to the area of maximal reste-
osis, was located at the zone of DES overlap in 17 of the
5 (68%) lesions, within the proximal or distal stent area in
(16%) lesions, and within 5 mm of the proximal or distal
tent edges in another 4 (16%) lesions (p for trend 0.01).
n 18 lesions, restenoses were classified as focal (72%), as
ultifocal in 3 (12.0%), and as diffuse in the remaining 4
16.0%). Among lesions classified as having a focal resteno-
is, 6 had total occlusion. Focal restenoses predominantly
ccurred in the overlapping stent zone; 3 (50%) of 6 cases
ith total occlusion and 9 (75%) of 12 cases without total
cclusion were found at the zone of stent overlap. Figure 3
hows a representative example of focal restenosis associated
ith stent overlap, and Figure 4 shows an example of a
esion with stent overlap and subsequent total occlusion.
iscussion
n this analysis of the 3 years of follow-up of the SIRTAX
rial, we found patients with DES overlap at increased risk
f MACE, including repeat revascularization and ischemic
dverse events. At 1 month, there was little evidence of
ncreased rates of MACE associated with DES overlap, but
5% CIs were wide and we cannot exclude substantial
ifferences among groups. Clinical findings at 9 months and
years of worse outcomes in patients with overlap were
choed by inferior angiographic outcomes at 8 months.
wenty-five patients with DES overlap and available an-
iographic data underwent TLR of a lesion. Among these,
2 (48%) had focal restenosis or total occlusion at the site of
verlap and an additional 5 (20%) had diffuse restenosis
ith the minimal lumen diameter located at the site of
verlap. The most frequent reasons for DES overlap were
n excessive lesion length in relation to maximal available
tent length and insufficient lesion coverage, whereas peris-
ent or guiding catheter dissections were rare.
tudy strengths and limitations. Our analysis is based on
he nearly complete follow-up of the SIRTAX trial, a
andomized superiority trial in an unselected all-comer
opulation seen at 2 major cardiovascular centers in Swit-
erland. Allocation of patients was concealed, treatment
rotocols were standardized, there was active follow-up of
atients with blinded adjudication of clinical events, and the
nalysis was according to the intention-to-treat principle
18). A major limitation of this and any other study
omparing outcomes in patients with and without overlap is
he selection of control individuals, which is inherently
elated to prognosis. Patients with stent overlap tend to have
ore, longer, and more complex lesions than controls, and
tatistical attempts to control the resulting confounding may
nly be partially successful. We therefore opted for compar-
ng patients with stent overlap with 2 different groups: 1
roup of patients with multiple DES within a vessel but no
Clinical Events at 3 YearsTable 5 Clinical Events at 3 Years
Multiple Stents
Single Stent (C)‡
Crude Analysis Adjusted Analysis§
Overlap (A)* No Overlap (B)†
A vs. B
HR (95% CI)
A vs. C
HR (95% CI) p Value
A vs. B
HR (95% CI)
A vs. C
HR (95% CI) p Value
Total no. of patients 134 199 679
Death 13 (9.7) 17 (8.5) 36 (5.3) 1.13 (0.55–2.33) 1.86 (0.99–3.51) 0.08 1.80 (0.80–4.05) 2.36 (1.08–5.15) 0.09
Cardiac death 6 (4.5) 10 (5.0) 24 (3.5) 0.89 (0.32–2.44) 1.29 (0.53–3.15) 0.58 1.41 (0.45–4.39) 1.43 (0.47–4.34) 0.78
MI 11 (8.2) 12 (6.0) 32 (4.7) 1.36 (0.60–3.09) 1.79 (0.90–3.55) 0.23 1.93 (0.72–5.21) 1.76 (0.75–4.11) 0.31
Q-wave 4 (3.0) 5 (2.5) 10 (1.5) 1.19 (0.32–4.42) 2.07 (0.65–6.59) 0.38 1.79 (0.42–7.62) 3.91 (1.05–16.64) 0.13
Non–Q-wave 7 (5.2) 7 (3.5) 22 (3.2) 1.48 (0.52–4.23) 1.64 (0.70–3.84) 0.52 2.19 (0.54–8.78) 1.00 (0.32–3.11) 0.48
Death or MI 23 (17.2) 28 (14.1) 62 (9.1) 1.22 (0.70–2.11) 1.93 (1.20–3.12) 0.01 1.75 (0.91–3.34) 2.28 (1.26–4.12) 0.02
TLR 27 (20.2) 32 (16.1) 66 (9.7) 1.26 (0.76–2.11) 2.19 (1.40–3.42) 0.01 1.94 (1.05–3.58) 1.33 (0.75–2.35) 0.10
Percutaneous 26 (19.4) 26 (13.1) 58 (5.5) 1.51 (0.88–2.60) 2.40 (1.51–3.81) 0.01 2.06 (1.09–3.90) 1.35 (0.74–2.46) 0.08
Surgical 2 (1.5) 8 (4.0) 13 (1.9) 0.37 (0.08–1.72) 0.79 (0.18–3.49) 0.18 0.89 (0.13–4.86) 1.07 (0.22–5.35) 0.93
Target vessel revascularization 30 (22.4) 39 (19.6) 81 (11.9) 1.15 (0.71–1.85) 2.00 (1.31–3.04) 0.01 1.87 (1.06–3.31) 1.16 (0.68–1.99) 0.08
Percutaneous 29 (21.6) 34 (17.1) 73 (10.8) 1.28 (0.78–2.11) 2.15 (1.40–3.30) 0.01 1.88 (1.05–3.39) 1.18 (0.68–2.05) 0.09
Surgical 2 (1.5) 8 (4.0) 13 (1.9) 0.37 (0.08–1.72) 0.79 (0.18–3.49) 0.18 0.79 (0.13–4.86) 1.07 (0.22–5.35) 0.93
Definite stent thrombosis 6 (4.5) 8 (4.0) 22 (3.2) 1.10 (0.38–3.18) 1.41 (0.57–3.47) 0.69 1.66 (0.41–6.68) 1.09 (0.33–3.66) 0.75
MACEs 34 (25.4) 42 (21.1) 95 (14.0) 1.22 (0.77–1.91) 1.93 (1.30–2.85) 0.01 1.99 (1.16–3.41) 1.50 (0.91–2.46) 0.04
Target vessel failure 36 (26.9) 48 (24.1) 109 (16.1) 1.12 (0.73–1.72) 1.78 (1.22–2.59) 0.01 1.77 (1.06–2.95) 1.30 (0.80–2.09) 0.09
Values are n (%). *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without overlap. ‡Patients with a single stent in a vessel. §Adjusted for diabetes, lesion length, reference vessel diameter, number of lesions, stent
allocation, lesion classification, and the presence of acute coronary syndrome. p values for differences in hazards among groups in crude and adjusted analyses. Italics indicate pairwise comparisons that are statistically significant at the conventional 2-sided p  0.05 and
corresponding 95% confidence intervals not overlapping the line of no difference at 1.
CI  confidence interval; HR  hazard ratio; MACE  major adverse cardiac events; MI  myocardial infarction; TLR  target lesion revascularization.
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Impact of Stent Overlap March 23, 2010:1178–88verlap and 1 group with implantation of a single DES only
ithin a vessel. To ensure full transparency, we present
esults from both unadjusted analyses and analyses adjusted
or the most important confounding factors. It is the
onsistency of the different comparisons and of the crude
nd adjusted analyses that supports our conclusion that
Figure 1 Time to Event Curves for Various Clinical End Points
Kaplan-Meier cumulative event curves for major adverse cardiac events (MACE)
(A) (composite of cardiac death, myocardial infarction [MI], or ischemia-driven
revascularization of the target lesion), target lesion revascularization (TLR) (B), and
the composite of overall death or MI (C). p values are for differences in hazards
among groups in crude and adjusted analyses. DES  drug-eluting stent(s).patients with DES overlap are at increased risk of MACECl
i T T D C M D T T D M T
Va
lu
al
lo
c N
AV
p
among groups.
CI  confidence interval.
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March 23, 2010:1178–88 Impact of Stent OverlapFigure 2 Pattern of Restenosis in Patients With Overlapping Stents
The lesions of 25 patients with overlapping stents who underwent target lesion revascularization within the 3-year follow-up period are shown. This figure provides an
example of the different zones of a lesion (middle), a schematic representation of all 25 lesions, and the locations of binary restenosis represented by a blue-colored
bar (bottom) and a summary histogram of the distribution of zones affected by binary restenosis (top). The p value is for trend across ordered zones and derived from a
logistic regression model with robust sirolimus-eluting stents (see Methods section). p  0.01.ngiographic ResultsTable 7 Angiographic Results
Multiple Stents
Single Stent (C)
Difference (95% CI)
p Value*Overlap (A) No Overlap (B) A vs. B A vs. C
Total no. of lesions 81 177 413
Minimal lumen
diameter, mm
In-stent 2.30 0.71 2.44 0.55 2.57 0.54 0.14 (0.32 to 0.03) 0.27 (0.42 to0.11) 0.01
In-segment 2.18 0.73 2.31 0.61 2.39 0.64 0.12 (0.30 to 0.06) 0.20 (0.37 to0.04) 0.04
% diameter stenosis
In-stent 18.8 22.65 12.2 15.83 10.40 13.87 6.62 (1.18 to 12.05) 8.36 (3.45 to 13.28) 0.01
In-segment 21.2 23.90 16.0 18.02 16.28 18.34 5.21 (0.67 to 11.08) 4.95 (0.40 to 10.30) 0.17
Late loss, mm
In-stent 0.33 0.61 0.18 0.43 0.15 0.38 0.15 (0.00 to 0.30) 0.17 (0.04 to 0.31) 0.04
In-segment 0.36 0.63 0.22 0.45 0.24 0.49 0.14 (0.01 to 0.29) 0.12 (0.02 to 0.26) 0.18
Binary restenosis
In-stent 10 (12.4) 9 (5.1) 15 (3.6) 7.2 (0.1 to 14.6) 8.7 (1.8 to 12.7) 0.01
In-segment 12 (14.8) 14 (7.9) 33 (8.0) 6.9 (1.4 to 15.3) 6.8 (0.0 to 13.8) 0.13
alues aremean SD or n (%). All analyses are based on regressionmodels using robust sirolimus-eluting stents that accounted for the correlation of characteristics of lesions within patients. Italics indicate
airwise comparisons that are statistically significant at the conventional 2-sided p 0.05 and corresponding 95% confidence intervals not overlapping the line of no difference at 0. *p values for differences
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Impact of Stent Overlap March 23, 2010:1178–88ompared with any other group of patients. Ours is the only
tudy with a follow-up duration as long as 3 years and the
nly analysis to use multiple control groups and statistical
djustments to ensure optimal control of confounding.
tent overlap and outcome with BMS. Ellis et al. (19)
eported the outcome of 206 patients undergoing angio-
raphic follow-up at 6 months after Palmaz-Schatz BMS
Figure 3 Coronary Angiography of a Restenotic, Nonocclusive L
Angiograms before (A) and after (B) percutaneous coronary intervention in a patie
with a zone of overlap of 5.9 mm in length. (C) The patient presented 24 months
infarction and underwent urgent repeat angiography revealing a subtotal in-stent re
Figure 4 Coronary Angiography of a Restenotic, Total Occlusiv
(A) Subtotal occlusion of the right coronary artery was treated with a 28-mm drug-
distally with an overlapping zone of 3 mm. (C) The post-procedural result. (D) Afte
angina. Total occlusion was documented, and the site of occlusion was located wmplantation. Stent overlap was associated with a higher
ate of restenosis than single stents (64% overlap vs. 30% no
verlap, p  0.001). These findings were corroborated in
everal subsequent studies with multiple overlapping BMS
merging as independent predictor of restenosis (20,21).
ore recently, Kereiakes et al. (13) reported on the out-
omes of 703 patients with or without overlapping BMS. At
n Associated With DES Overlap
ted with overlapping drug-eluting stents (DES) (2 DES each, 33 mm in length),
he index procedure with a troponin-positive non–ST-segment elevation myocardial
sis at the site of DES overlap.
ion Associated With DES Overlap
stent (DES). (B) Due to excessive lesion length, an 8-mm DES was implanted
ars, the patient underwent angiography due to clinical symptoms of unstable
e previously determined site of overlap (OL).esio
nt trea
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r 3 ye
ithin th
1
h
T
o
a
i
h
(
o
S
c
r
e
p
m
h
w
a
m
p
P
p
m
B
r
P
T
i
w
(
o
s
c
p
c
w
s
(
f
3
c
d
t
p
u
t
o
c
o
d
c
p
a
h
t
r
g
h
D
a
h
fi
p
m
r
i
a
o
r
r
i
i
p
(
S
p
a
p
t
i
o
d
p
s
w
p
d
C
D
u
c
o
c
a
w
l
R
D
3
R
1187JACC Vol. 55, No. 12, 2010 Räber et al.
March 23, 2010:1178–88 Impact of Stent Overlap-year follow-up, overlapping BMS were associated with a
igher rate of MACE, mainly driven by a greater need for
LR (28.2% with overlapping BMS vs. 16.8% without
verlapping BMS, p  0.01). BMS overlap also resulted in
higher rate of periprocedural MI (3.4% vs. 0.9%, p 0.03)
n this study. Similarly, Kornowski et al. (22) observed a
igher incidence of non–Q-wave MIs in patients with
22.8%) as compared to patients without (13.4%) BMS
verlap (p  0.005).
tent overlap and outcome with DES. Although DES
ompared with BMS have significantly reduced the risk of
estenosis, knowledge regarding the early and late safety and
fficacy of DES in the presence of stent overlap is incom-
lete. Data from the subgroup of 379 patients receiving
ultiple overlapping stents included in TAXUS V showed
igher rates of periprocedural MIs with PES (8.3%) than
ith BMS (3.3%, p  0.047) (15). Detailed angiographic
nalysis revealed a greater degree of side-branch compro-
ise with PES compared with BMS during the procedure,
otentially related to the thicker polymer-coated struts of
ES. In contrast, repeat revascularization (12.6% vs. 28.2%,
 0.001) and MACE (20.4% vs. 32.0%, p  0.01) at 9
onths were less frequent with overlapping PES than
MS. Dawkins et al. (23) noted a trend towards higher
ates of periprocedural MIs in patients with overlapping
ES (7.6%) than BMS (1.6%) (p  0.21) included in
AXUS VI. During a follow-up of 9 months, the difference
n MIs decreased, whereas rates of repeat revascularization
ere significantly lower with PES (1.6%) than with BMS
25.0%) (p  0.001) (23). Similarly, Ruchin et al. (24)
bserved a high rate of periprocedural MIs (12.9%) in a
eries of 318 patients treated with overlapping SES (24). In
ontrast, Kereiakes et al. (13) reported a similar incidence of
eriprocedural MIs and MACE in a pooled analysis of 5
linical trials in 1,034 patients. At 1-year follow-up, there
ere no significant differences among overlapping and
ingle SES with respect to MACE (p  0.70) and TLR
p  0.30). However, these analyses were typically based on
ollow-up durations of only 1 year. Our analysis is based on
years of follow-up. When visually exploring patterns of
umulative event curves (Fig. 1), it becomes obvious that
ifferences become more pronounced after termination of
he follow-up at 1-year.
Our findings are biologically plausible. Analysis of the
attern of restenosis in patients with DES overlap who
nderwent TLR during the follow-up period revealed that
he maximal lumen narrowing occurred at sites of DES
verlap in the majority of patients, which in turn suggests a
ausal link between overlap and risk of restenosis. We can
nly speculate as to the mechanism of the increased risk of
eath or MI found in our study. Experimental studies raised
oncerns regarding both the safety and efficacy of overlap-
ing DES because of the increased density of polymer, drug,
nd stent material. Decreasing efficacy of overlapping PES
as been observed, for example, with increasing follow-up
ime in a porcine coronary artery model (25). Finn et al. (17)eported signs of incomplete and delayed endothelialization,
reater accumulated fibrin deposition as markers of delayed
ealing, and increased inflammation at sites of overlapping
ES in rabbit iliac arteries. Incomplete endothelialization
nd increased inflammation at sites of overlapping DES
ave also been found in a porcine restenosis model (26). Our
ndings are also corroborated by a recent cohort study in
atients who had undergone DES implantation. During a
ean follow-up period of 399 days, Alfonso et al. (27)
eported a coronary artery aneurysm rate of 1.3% after DES
mplantation. In 4 of 15 patients with a documented
neurysm, the aneurysm was found at the zone of stent
verlap, which suggests excessive vessel remodeling as a
esult of the high density of drug or polymer. Another
ecent clinical investigation with angioscopy demonstrated
ncomplete neointimal coverage after SES, but not BMS,
mplantation at 2 years of follow-up. This phenomenon was
articularly pronounced in 4 patients with DES overlap
28). Using optical coherence tomography 6 months after
ES implantation, Matsumoto et al. (29) observed incom-
lete stent strut coverage in the majority of patients (84%)
nd overlapping SES showed a higher rate of strut malap-
osition than nonoverlapping SES (8% vs. 0.8%, respec-
ively; p  0.0001). Although the findings from these
maging studies were not associated with adverse clinical
utcomes, they may contribute to ischemic adverse events
uring longer term follow-up, particularly after dual anti-
latelet therapy was terminated. Although we observed
imilar rates of stent thrombosis among DES with and
ithout overlap in the present study, much larger patient
opulations would be required to statistically establish
ifferences between both groups.
onclusions
ES overlap occurs in a considerable proportion of patients
ndergoing percutaneous coronary intervention in routine
linical practice. The most common reasons for DES
verlap are excessive lesion length and incomplete lesion
overage. DES overlap does not seem to be associated with
n increased risk of periprocedural MI, but is associated
ith impaired clinical and angiographic outcomes during
ong-term follow-up.
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